Needham & Company Reiterates Avrobio (AVRO) at Outperform, $8 PT, Remains Supporter of Company's LV Based Gene Therapy Programs
Tweet Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and $8.00 price target on Avrobio Inc. (NASDAQ: AVRO), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
